374 related articles for article (PubMed ID: 2564628)
21. Mechanisms of resistance to etoposide and teniposide in acquired resistant human colon and lung carcinoma cell lines.
Long BH; Wang L; Lorico A; Wang RC; Brattain MG; Casazza AM
Cancer Res; 1991 Oct; 51(19):5275-83. PubMed ID: 1717144
[TBL] [Abstract][Full Text] [Related]
22. Energy-dependent reduced drug binding as a mechanism of Vinca alkaloid resistance in human leukemic lymphoblasts.
Beck WT; Cirtain MC; Lefko JL
Mol Pharmacol; 1983 Nov; 24(3):485-92. PubMed ID: 6579344
[TBL] [Abstract][Full Text] [Related]
23. Development and characterization of a WEHI-3B D+ monomyelocytic leukemia cell line resistant to novobiocin and cross-resistant to other topoisomerase II-targeted drugs.
Rappa G; Lorico A; Sartorelli AC
Cancer Res; 1992 May; 52(10):2782-90. PubMed ID: 1316227
[TBL] [Abstract][Full Text] [Related]
24. Trifluoperazine modulation of resistance to the topoisomerase II inhibitor etoposide in doxorubicin resistant L1210 murine leukemia cells.
Kamath N; Grabowski D; Ford J; Drake F; Kerrigan D; Pommier Y; Ganapathi R
Cancer Commun; 1991 Feb; 3(2):37-44. PubMed ID: 1995027
[TBL] [Abstract][Full Text] [Related]
25. In vitro multidrug resistance of P388 murine leukemia selected for resistance to diaziquone.
Gutierrez PL; Wilder PJ; Biswal N
Cancer Commun; 1989; 1(3):181-90. PubMed ID: 2576972
[TBL] [Abstract][Full Text] [Related]
26. Combined modalities of resistance in etoposide-resistant human KB cell lines.
Ferguson PJ; Fisher MH; Stephenson J; Li DH; Zhou BS; Cheng YC
Cancer Res; 1988 Nov; 48(21):5956-64. PubMed ID: 2844393
[TBL] [Abstract][Full Text] [Related]
27. Multidrug resistance in cells transfected with human genes encoding a variant P-glycoprotein and glutathione S-transferase-pi.
Fairchild CR; Moscow JA; O'Brien EE; Cowan KH
Mol Pharmacol; 1990 Jun; 37(6):801-9. PubMed ID: 1972772
[TBL] [Abstract][Full Text] [Related]
28. Altered topoisomerase II alpha in a drug-resistant small cell lung cancer cell line selected in VP-16.
Mirski SE; Evans CD; Almquist KC; Slovak ML; Cole SP
Cancer Res; 1993 Oct; 53(20):4866-73. PubMed ID: 8104687
[TBL] [Abstract][Full Text] [Related]
29. Mechanisms of multidrug resistance in HL60 cells: evidence that a surface membrane protein distinct from P-glycoprotein contributes to reduced cellular accumulation of drug.
McGrath T; Center MS
Cancer Res; 1988 Jul; 48(14):3959-63. PubMed ID: 2898287
[TBL] [Abstract][Full Text] [Related]
30. Sequential emergence of distinct resistance phenotypes in murine erythroleukemia cells under adriamycin selection: decreased anthracycline uptake precedes increased P-glycoprotein expression.
Slapak CA; Daniel JC; Levy SB
Cancer Res; 1990 Dec; 50(24):7895-901. PubMed ID: 1979251
[TBL] [Abstract][Full Text] [Related]
31. Reduced DNA topoisomerase II activity and drug-induced DNA cleavage activity in an adriamycin-resistant human small cell lung carcinoma cell line.
de Jong S; Zijlstra JG; de Vries EG; Mulder NH
Cancer Res; 1990 Jan; 50(2):304-9. PubMed ID: 1967222
[TBL] [Abstract][Full Text] [Related]
32. Atypical multidrug resistance in a therapy-induced drug-resistant human leukemia cell line (LALW-2): resistance to Vinca alkaloids independent of P-glycoprotein.
Haber M; Norris MD; Kavallaris M; Bell DR; Davey RA; White L; Stewart BW
Cancer Res; 1989 Oct; 49(19):5281-7. PubMed ID: 2569932
[TBL] [Abstract][Full Text] [Related]
33. Non-P-glycoprotein-mediated multidrug resistance in a small cell lung cancer cell line: evidence for decreased susceptibility to drug-induced DNA damage and reduced levels of topoisomerase II.
Cole SP; Chanda ER; Dicke FP; Gerlach JH; Mirski SE
Cancer Res; 1991 Jul; 51(13):3345-52. PubMed ID: 1675932
[TBL] [Abstract][Full Text] [Related]
34. Differential oxygen radical susceptibility of adriamycin-sensitive and -resistant MCF-7 human breast tumor cells.
Mimnaugh EG; Dusre L; Atwell J; Myers CE
Cancer Res; 1989 Jan; 49(1):8-15. PubMed ID: 2535695
[TBL] [Abstract][Full Text] [Related]
35. Multidrug resistance in a human leukemic cell line selected for resistance to trimetrexate.
Arkin H; Ohnuma T; Kamen BA; Holland JF; Vallabhajosula S
Cancer Res; 1989 Dec; 49(23):6556-61. PubMed ID: 2573416
[TBL] [Abstract][Full Text] [Related]
36. Progressive resistance to doxorubicin in mouse leukemia L1210 cells with multidrug resistance phenotype: reductions in drug-induced topoisomerase II-mediated DNA cleavage.
Ganapathi R; Grabowski D; Ford J; Heiss C; Kerrigan D; Pommier Y
Cancer Commun; 1989; 1(4):217-24. PubMed ID: 2576973
[TBL] [Abstract][Full Text] [Related]
37. Drug transport mechanisms in HL60 cells isolated for resistance to adriamycin: evidence for nuclear drug accumulation and redistribution in resistant cells.
Marquardt D; Center MS
Cancer Res; 1992 Jun; 52(11):3157-63. PubMed ID: 1591727
[TBL] [Abstract][Full Text] [Related]
38. Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue.
Hendricks CB; Rowinsky EK; Grochow LB; Donehower RC; Kaufmann SH
Cancer Res; 1992 Apr; 52(8):2268-78. PubMed ID: 1348448
[TBL] [Abstract][Full Text] [Related]
39. Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin.
Jain N; Lam YM; Pym J; Campling BG
Cancer; 1996 May; 77(9):1797-808. PubMed ID: 8646677
[TBL] [Abstract][Full Text] [Related]
40. Multidrug resistance in mitoxantrone-selected HL-60 leukemia cells in the absence of P-glycoprotein overexpression.
Harker WG; Slade DL; Dalton WS; Meltzer PS; Trent JM
Cancer Res; 1989 Aug; 49(16):4542-9. PubMed ID: 2568172
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
